| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.2 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.2 |